Table 1.
Baseline characteristics of the study population according to plasma amyloid-β status.
| Variables | Total | High plasma Aβ42/40 (>0.107) | Low plasma Aβ42/40 (≤0.107) |
|---|---|---|---|
| N (%) | 477 | 318 (66.7) | 159 (33.3) |
| Age (years) | 76.8 (4.5) | 76.5 (4.5) | 77.5 (4.6)* |
| Sex (female) | 283 (59.3) | 203 (63.8) | 80 (50.3)† |
| MAPT groups | |||
| Multidomain intervention + omega-3 | 128 (26.8) | 93 (29.3) | 35 (22.0) |
| Omega-3 | 111 (23.3) | 72 (22.6) | 39 (24.5) |
| Multidomain intervention | 118 (24.7) | 81 (25.5) | 37 (23.3) |
| Placebo | 120 (25.2) | 72 (22.6) | 48 (30.2) |
| Education | |||
| No diploma or primary school certificate | 121 (25.7) | 76 (24.3) | 45 (28.7) |
| Secondary education | 155 (33.0) | 95 (30.3) | 60 (38.2) |
| High school diploma | 67 (14.3) | 52 (16.6) | 15 (9.5) |
| University level | 127 (27.0) | 90 (28.8) | 37 (23.6) |
| Fried frailty phenotype | |||
| Robust (0/5) | 220 (52.5) | 138 (49.1) | 82 (59.4) |
| Pre-frail (1–2/5) | 183 (43.7) | 130 (46.3) | 53 (38.4) |
| Frail (≥3/5) | 16 (3.8) | 13 (4.6) | 3 (2.2) |
| CDR | |||
| Score 0 | 209 (43.8) | 147 (46.2) | 62 (39.0) |
| Score 0.5 or 1 | 268 (56.2) | 171 (53.8) | 97 (61.0) |
| MMSE | 27.9 (1.9) | 27.9 (1.9) | 27.7 (1.9) |
| Body mass index (kg/m2) | 26.5 (4.0) | 26.6 (4.2) | 26.3 (3.6) |
| APOE ε4 carriers | 121 (27.9) | 61 (21.4) | 60 (40.5)† |
| Plasma Aβ42/40, median (IQR) | 0.103 (0.113, 0.123) | 0.120 (0.110, 0.130) | 0.100 (0.090, 0.100)† |
Values presented in number (%) for categorical variables or mean (standard deviation) for continuous variables, unless otherwise indicated.
Aβ, amyloid-beta; APOE, Apolipoprotein E; AD, Alzheimer’s disease; CDR, Clinical Dementia Rating scale; IQR, interquartile range; MAPT, Multidomain Alzheimer Preventive Trial; MMSE, Mini-Mental State Examination (0–30, 0 is worse).
*
p<0.05
†
p<0.01 between two groups determined by Student’s t-test or by Chi-square/Fisher exact test.